Oppenheimer analyst Suraj Kalia raised the price target on ResMed (NYSE: RMD) to $212.00 (from $200.00) while maintaining an Outperform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE